News | Congenital Heart | September 09, 2016

Risk Factors for Congenital Heart Defects May Lie Both Inside and Outside the Heart

UCI biologists find role of genes in CHD is more complex than previously realized

congenital heart defects, CHD, risk factors, genes, University of California Irvine research

September 9, 2016 — New research published Sept. 8 in the Open Access journal PLOS Biology reports the role of genes in congenital heart defects (CHD) is more complex than previously realized. The research conducted University of California Irvine biologists Anne Calof and Arthur Lander and colleagues also found that overall risk is determined by a combination of gene effects both inside and outside of the heart itself.

CHDs are a leading cause of birth defect-related deaths. Understanding how genetic alterations cause such defects is complicated by the fact that many of the critical genes are unknown, and those that are known often contribute only small increases in CHD risk.

Normal heart formation depends on interactions of multiple types of cells that collaborate in precise times and places throughout development to build the heart’s intricate structures. To figure out how these interactions can go awry, the Calof-Lander team studied atrial septal defects (ASDs, a common type of heart defect) in a mouse model of the developmental disorder Cornelia de Lange Syndrome (CdLS).

Most cases of CdLS are caused by mutations that inactivate a single copy of Nipbl, a gene that directs the expression of many hundreds of other genes in tissues throughout the body. Just as people with CdLS have a high incidence of heart defects, 30 percent of mice that harbor similar Nipbl mutations exhibit atrial septal defects.

Employing genetically modified mouse models, the researchers used a novel technology to selectively introduce or remove Nipbl mutations in different tissues during embryonic development. Unexpectedly, they found that no Nipbl deficiency in any single tissue — including the tissue that forms the heart itself — could singlehandedly account for the development of atrial septal defects. Rather, the development of heart defects was determined by interactions between heart-forming tissues and the rest of the body. In fact, Nipbl deficiency in some tissues even seemed to protect against the development of atrial septal defects, in certain situations.

In a Primer article that accompanies this research, Bruce Gelb, M.D., from the Icahn School of Medicine at Mount Sinai, explains why these were “mind-bending results” and writes that “this work provides novel insights into incomplete penetrance and oligogenic effects underlying CHD.” He adds that the novel observations “add further complexity to the way in which we need to think about CHD pathogenesis.”

“Our results lead us to hypothesize that heart defects such as ASDs occur when the heart does not grow quickly enough to meet the demands of the developing body — in other words, that heart size and body size must be coordinated for the heart to develop without defects,” said Calof, professor of anatomy & neurobiology and developmental & cell biology at UCI. “To our knowledge, this is the first genetic demonstration that major risk factors for heart defects are likely to lie outside of the heart itself.”

“When a single gene change causes a birth defect, we often assume that it’s because one thing goes wrong in one cell type. The big difference in our studies may have to do with the fact that Nipbl controls a large number of other genes,” said Lander, the Donald Bren Professor of Developmental & Cell Biology and director of UCI’s Center for Complex Biological Systems. “Given that most human CHDs are now thought to be caused by gene variants acting in combination, what we learned from Nipbl-deficient mice may actually be more typical of the way most CHDs arise.”

Calof and Lander, working together with researchers at Children’s Hospital of Philadelphia, helped identify Nipbl, the causative gene for Cornelia de Lange Syndrome, in 2004. The discovery has led to the development of tools for molecular diagnosis of CdLS and has spawned a large body of biomedical research on CdLS and related syndromes. As part of this effort, Calof, Lander and their UCI colleague Thomas Schilling, professor of developmental nd cell biology, have developed animal models of CdLS that are being used to find ways to prevent and/or treat this disorder. Their work has been recognized by the CdLS Foundation, and UCI has been designated a Center of Research Excellence in Cornelia de Lange Syndrome.

In addition to Calof and Lander, Rosaysela Santos, Shimako Kawauchi, Martha Lopez-Burks, Hojae Choi and Jamie Wikenheiser from UCI; Russell Jacobs from Caltech; Benedikt Hallgrimsson and Heather Jamniczky from the University of Calgary, Canada; and Scott Fraser from the University of Southern California contributed to the study, which was funded in part by the National Institute of Child Health and Human Development (grant number NICHD P01-HD052860) and National Institute of Biomedical Imaging and Bioengineering (grant number NIBIB R01-EB000993).

For more information: www.journals.plos.org/plosbiology

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init